PRIVA-TRAMADOL/ACET TABLET

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

Pieejams no:

PHARMAPAR INC

ATĶ kods:

N02AJ13

SNN (starptautisko nepatentēto nosaukumu):

TRAMADOL AND PARACETAMOL

Deva:

325MG; 37.5MG

Zāļu forma:

TABLET

Kompozīcija:

ACETAMINOPHEN 325MG; TRAMADOL HYDROCHLORIDE 37.5MG

Ievadīšanas:

ORAL

Vienības iepakojumā:

60/100

Receptes veids:

Narcotic (CDSA I)

Ārstniecības joma:

OPIATE AGONISTS

Produktu pārskats:

Active ingredient group (AIG) number: 0250601001; AHFS:

Autorizācija statuss:

CANCELLED POST MARKET

Autorizācija datums:

2020-10-13

Produkta apraksts

_ _
_ _
_Priva-TRAMADOL/ACET_
Page 1 of 68
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
PRIVA-TRAMADOL/ACET
Acetaminophen and Tramadol Hydrochloride Tablets, Pharmapar Std.
37.5 mg Tramadol Hydrochloride/325 mg Acetaminophen
Centrally Acting Analgesic
Pharmapar Inc.
Date of revision:
1565, boul. Lionel-Boulet
January 30, 2020
Varennes, QC
J3X1P7
Control # 234260
_ _
_ _
_Priva-TRAMADOL/ACET_
Page 2 of 68
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
5
ADVERSE REACTIONS
.................................................................................................
17
DRUG INTERACTIONS
.................................................................................................
21
DOSAGE AND ADMINISTRATION
.............................................................................
27
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 31
STORAGE AND STABILITY
.........................................................................................
38
SPECIAL HANDLING INSTRUCTIONS
......................................................................
38
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 38
PART II: SCIENTIFIC INFORMATION
...............................................................................
40
PHARMACEUTICAL INFORMATION
.........................................................................
40
CLINICAL TRIALS
...................................................................................